Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD
Price: $166.05 Analyst target: $206.22 Upside: 24.19%
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.